FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients with PSMA Positive mCRPC By Ogkologos - April 25, 2025 815 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAfore study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Foodie Fridays: It’s Cucumber Season! July 23, 2021 37-Year-Old Mom Breaks American Marathon Record January 21, 2022 Mom Fighting Breast Cancer Says Her Haunted House Is Something To... October 30, 2019 Molecular Analysis for Precision Oncology Congress 2022, 14-16 October 2022, Amsterdam,... September 29, 2022 Load more HOT NEWS As Winter Storms Plague Southern States, GreaterGood Is Helping Where It’s... Cancer Surgery Unexpectedly Canceled for Mother of Two, Who Says It’s... Long-Term Outcomes Suggest a Sustained Clinical Benefit to Metastasis-Directed Treatment Over... Novel Checklist for Quality of Life to Bring ESMO-MCBS and Clinical...
